Over 50,000 patients treated with RenalGuard 

RenalGuard is designed to reduce the toxic effects of contrast media on the kidneys, which may lead to a reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients. RenalGuard Therapy is based on existing published literature, including the PRINCE study, which supports the theory that creating and maintaining a high urine output through the kidneys allows the body to eliminate contrast, reducing its toxic effects rapidly.

RenalGuard Solutions

Demonstration of how RenalGuard can help reduce the chance of kidney injury in high risk patients.

RenalGuard SetUp


We constantly update this page with the latest publications.  If you still can’t find what you’re looking for, need more information about Tricvalve please feel free to get in touch with us – we will be more than happy to help.

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.